Taysha Gene Therapies, Inc. Annual Report - How They Did This Year

First Look: Who is Taysha Gene Therapies?

This report covers Taysha Gene Therapies' activities for the fiscal year that ended on December 31, 2025.

Taysha is considered a "Smaller reporting company." This means they are a smaller business. They meet SEC rules for companies with less than $700 million in publicly traded shares. This is measured at the end of their last second three-month period. Or, they have under $100 million in yearly sales. In that case, their publicly traded shares must be under $250 million from their last full year.

Because of this status, their reports follow different rules than larger companies. For example, they provide two years of checked financial reports instead of three. They also share fewer details on executive pay. Plus, there's no auditor's check on their financial systems. This means they operate under different reporting requirements. For investors, this means you'll have a different level of detail to consider. Smaller companies can also see bigger swings in stock price, and fewer experts might follow them.

As of June 30, 2025, their shares available to trade were worth about $544.8 million. This value is an important number. It shows their 'Smaller reporting company' status. It also gives you an idea of their market size.

We also see some important activities. These include partnerships with companies like Astellas. They also involve raising money (like selling new shares or private investments). And they have loan agreements (like the "Trinity Term Loans"). Taysha is a biotech company in clinical trials. It's not yet earning sales. It focuses on developing new treatments. So, these activities are very important.

Partnerships, like with Astellas, are key. Astellas is a major global drug company. These deals often include initial payments and payments for reaching goals. They also share development costs. This brings in money without reducing your ownership percentage. It also uses a larger partner's knowledge and resources. This helps develop treatments and bring them to market.

Raising money is Taysha's main way to get funds. This includes selling new shares to the public. It also includes selling shares to private investors. This money funds costly clinical trials. It also supports continued gene therapy research.

Loan agreements, like the "Trinity Term Loans," also provide money. These loans often give the company more time with its cash. They can be a way to get money without issuing as many new shares. But they come with interest payments and rules they must follow. This shows they actively fund operations and develop treatments. This is typical for a biotech company. They need a lot of money before selling a product.